이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Thread Embedding Acupuncture Added to Antihistamine Treatment for Chronic Urticaria

2026년 11월 12일 업데이트: Do Thanh Sang, University of Medicine and Pharmacy at Ho Chi Minh City

Evaluation of the Efficacy and Safety of Thread Embedding Acupuncture Combined With an H1 Antihistamine for the Treatment of Chronic Urticaria

This study will test whether adding thread embedding acupuncture to an antihistamine helps adults with chronic hives whose symptoms remain bothersome despite taking the antihistamine. In thread embedding acupuncture, a clinician uses a needle to place a small dissolvable thread at an acupuncture point. The comparison procedure uses the same acupuncture points and a needle, without placing a thread. Both groups take cetirizine.

The researchers plan to enroll 124 adults at three hospitals in Ho Chi Minh City, Vietnam. Participants will be assigned by chance to one of the two groups. They will receive two procedures, two weeks apart. Participants and the people who assess their symptoms will not know which procedure they received. The main assessment compares changes in hives and itching after four weeks. The study will also assess quality of life, a blood marker called total immunoglobulin E, additional antihistamine use, side effects, and whether symptoms return during follow-up through week 8.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

This multicenter, randomized, sham-controlled, parallel-group trial compares polydioxanone (PDO) thread embedding acupuncture plus cetirizine with sham thread embedding acupuncture plus cetirizine. Eligible adults will complete a 7-day run-in with oral cetirizine 10 mg daily and a daily hives and itch diary. Participants with a 7-day Urticaria Activity Score (UAS7) of at least 16 and a weekly itch score of at least 8 after run-in are eligible for randomization.

The trial plans to randomize 124 participants in a 1:1 ratio using concealed block randomization through REDCap. Participants and outcome assessors are masked to allocation. The statistician will analyze coded groups. Clinicians performing the procedure know the assignment. Procedures are scheduled at baseline and week 2, with a 4-week treatment period and a further 4 weeks of follow-up. The primary analysis compares change from baseline in UAS7 at week 4. Other assessments include UAS7 at weeks 2 and 8, urticaria-related quality of life, serum total IgE, rescue medication use, adverse events, and symptom recurrence. Analyses are planned on an intention-to-treat basis.

연구 유형

중재적

등록 (추정된)

124

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Sang Thanh Do, MD, MSc
  • 전화번호: +84 948 561 030
  • 이메일: dtsang@ump.edu.vn

연구 장소

      • Ho Chi Minh City, 베트남
        • Ho Chi Minh City Traditional Medicine Hospital, Outpatient Department
      • Ho Chi Minh City, 베트남
        • Le Van Thinh Hospital, Department of Dermatology
      • Ho Chi Minh City, 베트남
        • University Medical Center Ho Chi Minh City, Branch 3

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age 18 years or older and willing to provide written informed consent.
  • Chronic urticaria diagnosed according to the EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline. Transient wheals and itching occur at least daily for more than 6 weeks despite prior or current use of an H1 antihistamine, without serious systemic symptoms. Individual wheals resolve within 30 minutes to 24 hours.
  • UAS7 of at least 16 and weekly itch score of at least 8 after the 7-day run-in.
  • No previous thread embedding acupuncture.

Exclusion Criteria:

  • Urticaria with an identified cause, including physical or mechanical urticaria.
  • Warning signs of systemic or autoinflammatory disease (e.g., Schnitzler syndrome or cryopyrin-associated periodic syndromes), or urticarial vasculitis.
  • Cutaneous mast cell disease or erythema multiforme.
  • Current or prior severe associated symptoms such as laryngeal edema, acute angioedema, anaphylaxis, or bradykinin-mediated angioedema including hereditary angioedema.
  • Other chronic pruritic skin disease that could interfere with assessment.
  • History of allergy to implant materials, especially absorbable suture or catgut, or a predisposition to keloid formation.
  • Current or recent immunosuppressive therapy or systemic corticosteroids within 2 to 4 weeks (or 30 days) before participation, as specified in the protocol.
  • Biologics such as omalizumab, leukotriene receptor antagonists, or H2 antihistamines within 7 to 14 days before screening or randomization, as specified in the protocol.
  • H1 antihistamine use above the recommended dose within 3 days before screening.
  • Psychotropic medication within the preceding month.
  • Malignancy or severe endocrine disorder.
  • Serious cardiovascular or cerebrovascular disease, diabetes mellitus, severe hepatic or renal failure, or a hematopoietic disorder.
  • Severe debilitation with reduced immune resistance.
  • Other serious systemic autoimmune disease, such as systemic lupus erythematosus.
  • Cognitive impairment, psychiatric illness, or a communication barrier that prevents participation in the treatment procedures.
  • A nonabsorbable implant at the intended procedure site.
  • Pregnancy, breastfeeding, or plans to become pregnant during the study.
  • Participation in another clinical trial in the preceding 3 months.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: PDO Thread Embedding Acupuncture Plus Cetirizine

Participants receive polydioxanone (PDO) thread embedding acupuncture at baseline and week 2, plus oral cetirizine as background treatment.

An absorbable monofilament polydioxanone (PDO) thread is implanted at seven bilateral acupuncture points (14 sites) at baseline and week 2.

Both arms receive cetirizine 10 mg orally each morning during the 7-day run-in and 4-week treatment period. Additional cetirizine use for rescue is recorded.

가짜 비교기: Sham Thread Embedding Acupuncture Plus Cetirizine

Participants receive a sham procedure at the same acupuncture points at baseline and week 2. The clinician uses an empty needle, so no thread is implanted. Participants also receive oral cetirizine as background treatment.

Both arms receive cetirizine 10 mg orally each morning during the 7-day run-in and 4-week treatment period. Additional cetirizine use for rescue is recorded.

The clinician inserts and withdraws an empty needle at the same acupuncture points at baseline and week 2. The procedure leaves no implanted thread.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change From Baseline in 7-Day Urticaria Activity Score (UAS7) at Week 4
기간: Baseline and week 4

UAS7 is the sum of participant-reported daily hive and itch severity scores over seven consecutive days. The total ranges from 0 to 42, with higher scores indicating more severe symptoms. Change is calculated as the follow-up score minus baseline.

Baseline and week 4

2차 결과 측정

결과 측정
측정값 설명
기간
Change From Baseline in UAS7 at Weeks 2 and 8
기간: Baseline and weeks 2 and 8

UAS7 is the sum of participant-reported daily hive and itch severity scores over seven consecutive days. The total ranges from 0 to 42, with higher scores indicating more severe symptoms. Change is calculated as the follow-up score minus baseline.

Baseline and weeks 2 and 8
Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) Score
기간: Baseline and weeks 2, 4, and 8

Participants complete the disease-specific questionnaire about how chronic urticaria affected their lives in the preceding two weeks. Higher scores indicate greater impairment. Change is calculated as the follow-up score minus baseline.

Baseline and weeks 2, 4, and 8
Change From Baseline in Serum Total Immunoglobulin E (IgE)
기간: Baseline and week 4

Serum total IgE is measured by enzyme-linked immunosorbent assay (ELISA) and reported in IU/mL. Change is calculated as the week 4 concentration minus baseline.

Baseline and week 4
Proportion of Participants With Adverse Events
기간: From baseline through week 8

The study records adverse events and serious adverse events in each group during treatment and follow-up. Event severity is graded using the protocol-specified CTCAE criteria.

From baseline through week 8
Proportion of Participants Reporting Recurrence or Flare of Urticaria Symptoms
기간: Weeks 4 through 8

Participants are contacted by telephone at week 8 using a standardized script to determine whether symptoms returned or flared during the post-treatment follow-up.

Weeks 4 through 8
Number of Rescue Cetirizine Tablets Used
기간: From baseline through week 4

The total number of additional cetirizine tablets taken for symptom relief beyond the scheduled background dose is compared between groups.

From baseline through week 4

기타 결과 측정

결과 측정
측정값 설명
기간
Association of Baseline UAS7, Serum Total IgE, and Disease Duration With UAS7 at Week 4
기간: Baseline and week 4

A multivariable linear regression will estimate the association of each baseline factor with week 4 UAS7, adjusting for study group and site.

Baseline and week 4

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Sang Thanh Do, MD, MSc, University of Medicine and Pharmacy at Ho Chi Minh City

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2027년 7월 1일

기본 완료 (추정된)

2029년 2월 1일

연구 완료 (추정된)

2029년 3월 1일

연구 등록 날짜

최초 제출

2026년 11월 12일

QC 기준을 충족하는 최초 제출

2026년 11월 12일

처음 게시됨 (실제)

2026년 11월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 12일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 4861/ĐHYD-HĐĐĐ

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .